Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to Study A Novel Traumatic Brain Injury Treatment

Hackensack Meridian Neuroscience Institute at JFK University Medical Center

Hackensack Meridian Neuroscience Institute at JFK University Medical Center announced today that it has been awarded a major research grant from the National Institute of Neurological Disorders and Stroke, part of the U.S. National Institutes of Health, to study a novel approach on whether the blocking of formation of Neutrophil extracellular traps (NET) provides better outcomes after a Traumatic Brain Injury (TBI). The five-year award of $2,213,750 is part of the highly competitive NIH extramural grant application process that recognizes innovative scientific projects. NIH-funded research has led to scientific breakthroughs and new treatments that help people live longer, healthier lives.

Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy

The NIH grant will fund a project entitled “Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy” proposed by Mohammed Abdul Muneer, MSc, PhD, Research Scientist & Principal Investigator, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Associate Professor of Neurology at the Hackensack Meridian School of Medicine.

The work hypothesizes that inhibition of peptidyl arginine deiminase type 4 (PAD4), an enzyme required for NET formation, using PAD4 antagonistic peptide (PAP), will attenuate the formation of NET, NET-induced thrombosis, and will promote neovascularization and functional recovery after TBI.

Gregory J. Przybylski, M.D.

“We are honored to receive this prestigious NIH grant,” said Gregory J. Przybylski, M.D., MBA, chairman, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Professor of Neurosurgery at the Hackensack Meridian School of Medicine. “I congratulate Dr. Muneer and his team for this incredible achievement. This is yet another research grant that he has received from the NIH. It is a testament to his hard work, dedication, and leadership in the neuroscience field.”

The Muneer lab at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center seeks to demonstrate a unique therapeutic strategy for TBI focusing on the activation of leukocytes, especially neutrophils that cause the release of nuclear and granular contents to form an extensive web-like structure of DNA called neutrophil extracellular traps (NET). In TBI, the mechanism of injury-induced formation of NET and its mechanistic regulatory role in thrombosis have remained elusive. Moreover, it is unclear whether blocking NET formation provides better outcomes after TBI. Therefore, Dr. Muneer’s novel research efforts to suppress the formation of NET will provide critical information potentially supporting a valuable new therapeutic strategy to enhance functional recovery following TBI.

“My research team and I will study an approach to suppressing the formation of NET, which may be a valuable therapeutic strategy, and analyze the efficacy of the therapy in the functional recovery level after TBI,” said Dr. Muneer.

“The Neuroscience Institute at JFK University Medical Center has been in existence for over 30 years,” said Gay Holstein, PhD, translation research, Neuroscience Institute at JFK University Medical Center. “We are honored to receive this research grant and look forward to the findings.”

Ihor Sawczuk, M.D.

“TBI is such an omnipresent problem, it’s critical to have our talented researchers findings new ways to improve and lengthen lives for this significant patient population,” said Ihor Sawczuk, M.D., FACS, president of Academics, Research, and Innovation at Hackensack Meridian Health, founding chair of the Hackensack Meridian Health Research Institute, and associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version